Paving the Critical Path of Drug Development: the CDER Perspective
Overview
Authors
Affiliations
Improving the science of drug development and regulation is important in fulfilling the public health mission of the US Food and Drug Administration (FDA). A decade on from the launch of the Critical Path Initiative, the FDA's Center for Drug Evaluation and Research (CDER) is now participating in more than 20 science-driven consortia to achieve this goal.
Improving target assessment in biomedical research: the GOT-IT recommendations.
Emmerich C, Martinez Gamboa L, Hofmann M, Bonin-Andresen M, Arbach O, Schendel P Nat Rev Drug Discov. 2020; 20(1):64-81.
PMID: 33199880 PMC: 7667479. DOI: 10.1038/s41573-020-0087-3.
Brennan F, Cavagnaro J, McKeever K, Ryan P, Schutten M, Vahle J MAbs. 2017; 10(1):1-17.
PMID: 28991509 PMC: 5800363. DOI: 10.1080/19420862.2017.1389364.
Arneric S, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L J Alzheimers Dis. 2016; 55(1):19-35.
PMID: 27662307 PMC: 5115607. DOI: 10.3233/JAD-160573.
Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease.
Stephenson D, Hu M, Romero K, Breen K, Burn D, Ben-Shlomo Y J Parkinsons Dis. 2015; 5(3):581-94.
PMID: 26406139 PMC: 4887129. DOI: 10.3233/JPD-150570.
Biomarker development in the context of urologic cancers.
Kelloff G, Sigman C, Scher H Urol Oncol. 2015; 33(6):295-301.
PMID: 25746942 PMC: 4521394. DOI: 10.1016/j.urolonc.2015.01.007.